Selected Grants
Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
Clinical TrialPrincipal Investigator · Awarded by University of Michigan · 2024 - 2029Regeneron: III:REGN1979: A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 × ANTI-CD3BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (D
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029HCRN-LYM21-544
Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2024 - 2027Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma (Valemetostat tosylate [DS-3201b], an enhancer of zeste homolog [EZH] 1/2 dual inhibitor, for R/R PTCL)
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2022 - 2027: A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF DS-3201B IN SUBJECTS WITH LYMPHOMAS
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2021 - 2026A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigators Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) PTCL-001
Clinical TrialPrincipal Investigator · Awarded by University of Virginia - Charlottesville · 2024 - 2025A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) PTCL-001
Clinical TrialPrincipal Investigator · Awarded by University of Virginia - Charlottesville · 2024 - 2025A Phase I, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms
Clinical TrialPrincipal Investigator · Awarded by MacroGenics, Inc. · 2019 - 2024External Relationships
- Acrotech
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.